Background: In our companion paper, we reported that the phosphodiesterase type 4 inhibitor apremilast reduced ethanol (EtOH) intake and preference in different drinking models in male and female C57BL/6J mice. In this study, we measured the effects of apremilast on other behaviors that are correlated with EtOH consumption.
P
HOSPHODIESTERASE TYPE 4 (PDE4) inhibitors decrease ethanol (EtOH) seeking and consumption in rodent models Hu et al., 2011; Wen et al., 2012) and have been studied as potential treatments for neuroinflammatory diseases. However, clinical use of these drugs is limited by their gastrointestinal side effects. In our companion paper, we showed that apremilast, a PDE4 inhibitor with lower pro-emetic activity, produced stable decreases in EtOH intake in male and female C57BL/6J mice in different drinking tests (Blednov et al., 2018) . EtOH drinking may be positively or negatively correlated with other behaviors (Blednov et al., 2012; Green and Grahame, 2008) , and it is important to study the relevant behaviors to understand how apremilast decreases drinking and to further evaluate its potential as a repurposed drug for treating alcohol use disorder (AUD).
There is a strong positive correlation between consumption of EtOH and sweet solutions (Bachmanov et al., 1996; Blednov et al., 2008; Yoneyama et al., 2008) . EtOH drinking is also positively correlated with response to novelty (Blednov et al., 2012) and the rewarding properties of EtOH, as measured in the conditioned place preference (CPP) test (Green and Grahame, 2008) . Conditioned taste aversion (CTA) (Blednov et al., 2012; Green and Grahame, 2008; Risinger and Cunningham, 1998) and acute EtOH withdrawal severity are used as indices of the aversive effects of EtOH and are negatively correlated with voluntary EtOH consumption (Belknap et al., 2008; Hitzemann et al., 2009; Metten et al., 1998) . Duration of the loss of righting reflex (LORR) measures EtOH's hypnotic or sedative effects and is negatively correlated with the severity of acute EtOH withdrawal in mice (Blednov et al., 2012) . Increased sensitivity to sedation, ataxia, or other adverse effects would be expected to decrease the amount of EtOH consumed, although this is not always observed in rodent models.
In humans, AUD is also associated with negative reinforcing states. For example, individuals may drink alcohol to reduce anxiety or symptoms related to alcohol withdrawal. A large international study found a strong association between anxiety and alcohol and other substance use disorders, and the onset of anxiety disorders typically preceded that of drug abuse (Merikangas et al., 1998) , suggesting that alcohol's anxiolytic effects may be important in the initiation of drinking. Furthermore, a low level of response to alcohol was shown to be a predictor of future alcohol-related problems (Schuckit, 1994) . In addition to a subject's innate or initial sensitivity to EtOH, a major determinant of the level of response to EtOH is the ability to develop acute functional tolerance (AFT) during a single EtOH exposure. AFT is characterized by greater intoxication during the ascending phase of the blood EtOH concentration (BEC) curve than at equivalent concentrations on the descending phase. AFT has a genetic component and occurs in humans as well as in animal models (Bennett et al., 1993; Erwin and Deitrich, 1996; Radcliffe et al., 2006) . Decreased acute sensitivity to EtOH may be an important risk factor for the development of AUD.
Considering the EtOH-related behaviors discussed above and their contribution to drinking, it is relevant to examine the effects of potential drugs to treat AUD on these behaviors. In our companion article, we showed that apremilast reduced preference for EtOH but did not change preference for sweet solutions (Blednov et al., 2018) . In this study, we measured the effects of apremilast pretreatment on other relevant behaviors in both male and female mice. Apremilast increased the acute hypnotic and intoxicating effects of EtOH and reduced AFT. An increase in the aversive properties of EtOH could contribute to the ability of apremilast to reduce drinking.
MATERIALS AND METHODS

Mice
Male and female C57BL/6J mice were from a colony maintained in the Animal Resources Center at The University of Texas at Austin (UT Austin). Original breeders were purchased and replenished every 6 months from The Jackson Laboratory (Bar Harbor, ME). Mice were group-housed (4 or 5 per cage) in temperature-and humidity-controlled rooms with free access to food and water using a 12-hour light/dark cycle (lights on at 7:00 AM). Experiments began when the mice were 2 to 3 months old. Mice were allowed to adapt to the testing rooms for about 1 week before behavioral testing. Separate groups of mice were used for the different behavioral tests in this study and that of our companion paper (Blednov et al., 2018) , with the exception of the locomotor activity tests in which the same mice were used but different time periods were analyzed in the 2 studies. Experiments were approved by the Institutional Animal Care and Use Committee at UT Austin.
Drug Administration
Apremilast was purchased from Toronto Research Chemicals Inc. (Toronto, ON, Canada). It was freshly prepared as a suspension in saline with 3 to 4 drops of Tween-80 and administered daily in a volume of 0.05 ml/10 g of body weight 1 or 3 hours before experiments. Control mice received the same volume of saline containing 3 to 4 drops of Tween-80. Apremilast (20 mg/kg, p.o.) was given once daily for up to 6 days. This dose was chosen based on its ability to significantly reduce EtOH drinking in both the continuous and intermittent 2-bottle choice (2BC) tests without reducing total fluid intake (Blednov et al., 2018) . EtOH (Sigma-Aldrich, St. Louis, MO) was freshly prepared in saline and injected i.p. in a volume of 0.1 ml/10 g of body weight. Control mice received the same injection volume of saline.
Conditioned Taste Aversion
A negative correlation was observed between CTA and EtOH drinking, suggesting that EtOH's aversive properties may limit voluntary EtOH consumption (Risinger and Cunningham, 1998) . In CTA procedures, an association is established between an environmental, conditioned stimulus (e.g., sweet solution), and the unconditioned stimulus (e.g., EtOH). Mice were adapted to a waterrestricted schedule of 2 hours per day for 7 days. Saline or apremilast was given daily 3 hours before experimental or control (during intermittent days with limited access to water) sessions. At 48-hour intervals on days 1, 3, 5, 7, 9, and 11, mice received 1-hour access to saccharin (Sigma-Aldrich; 0.15% w/v sodium saccharin in tap water). For the first 4 days, mice received saline injections, and saccharin intake on day 3 (trial 0 in Figs 1 and 2) was used as the control measure (100%). Beginning on day 5 (trial 2 in Figs 1 and 2) , half of the mice received daily injections of saline and half received daily injections of apremilast. Immediately after 1-hour access to saccharin on day 5, mice were injected with saline, EtOH (2.5 g/kg), or lithium chloride (LiCl; 10 mEq/kg; Sigma-Aldrich). Mice had 30-minute access to tap water 5 hours after each saccharin-access period to prevent dehydration. On intervening days, mice had 2-hour access to water at standard times in the morning. Reduced consumption of saccharin was used to measure CTA. In a separate experiment, apremilast was used as the unconditioned stimulus and was injected instead of EtOH, after the saccharin sessions.
Conditioned Place Preference
The CPP protocol was carried out as described previously (Blednov et al., 2003) . Six acrylic boxes were individually enclosed in light-and sound-attenuating, ventilated chambers (Med Associates, St. Albans, VT). Each box consisted of 2 compartments containing a different floor type (either bars set in a grid or small round holes). Infrared light sources and photodetectors were used to measure general activity and location of the mouse in the left or right compartment. Total activity counts and location were computer recorded. Saline or apremilast was given daily 3 hours before the experimental session. Before training, na€ ıve mice were first habituated to chambers with covered floors; the next day mice received saline i.p. and were given 30-minute access to both chambers. The next day, half of the mice were designated for pretreatment with saline and the other half for pretreatment with apremilast. Half of the mice from each group were given EtOH (2 g/kg, i.p.) and placed in a conditioning chamber containing a bar floor for 5 minutes, and the other half were placed in a chamber containing a floor with round holes. The next day, mice were given an equivalent volume of saline i.p. and placed in the opposite chamber for 5 minutes. This pattern was repeated for 8 days (4 saline-and 4 EtOH-conditioning sessions). The other half of the mice received saline on conditioning days 1, 3, 5, and 7 and EtOH (2 g/kg, i.p.) on conditioning days 2, 4, 6, and 8.
Twenty-four hours after the last conditioning session, mice were given saline i.p. and then had access to both chambers for 30 minutes. The time spent in the EtOH-paired side during the habituation session was subtracted from the time spent in that side during the test session to determine a CPP score, which was compared with a theoretical mean of 0 (no CPP) and then compared between treatment groups. We also compared the time spent on the bar floor when it was paired with EtOH [Bar+] and when it was paired with saline [BarÀ] .
Conditioned Place Avoidance
The conditioned place avoidance (CPA) test was performed as described . Saline or apremilast was given daily 3 hours before the experimental session. The protocol was identical to the CPP test, except EtOH (2 g/kg, i.p.) was given immediately after the conditioned stimulus. Half of the mice from each group (pretreated with saline or apremilast) received EtOH after sessions on the floor with round holes, while the other half received EtOH after sessions on the bar floor. On alternate days, mice received injections of saline after placement on the opposite type of floor.
Acute Withdrawal from EtOH
Mice were scored for handling-induced convulsion (HIC) severity 30 minutes before and immediately before EtOH injection, and these predrug baseline scores were averaged. After injecting a single dose of EtOH in saline (4 g/kg, i.p.), the HIC score was measured every hour until the HIC level reached baseline. Acute withdrawal was measured as the area under the curve, above the predrug level (Crabbe et al., 1991) . To evoke HIC, an investigator picked up the mouse by the tail and, if necessary, gently rotated it 180°. The HIC was scored as follows: 5, tonic-clonic convulsion when lifted; 4, tonic convulsion when lifted; 3, tonic-clonic convulsion after a gentle spin; 2, no convulsion when lifted, but tonic convulsion elicited by a gentle spin; 1, facial grimace only after a gentle spin; 0, no convulsion or grimace when spun. Saline or apremilast (20 mg/kg) was given 1 hour before EtOH injection.
Elevated Plus Maze
The elevated plus maze was used to measure basal anxiety-like behavior and the effect of apremilast on EtOH-mediated anxiolyticlike behavior (Blednov et al., 2001 ). Mice were taken to the testing room 1 day before the experiment and were tested between 10:00 and 12:00 AM under ambient room light. Mice were weighed and injected with saline or EtOH (1.25 g/kg, i.p.) 5 minutes before the test. Each mouse was placed on the central platform of the maze facing an open arm and allowed to freely explore for 5 minutes, during which time the following measurements were recorded manually: number of open arm entries, number of closed arm entries, total number of entries, time spent in open arms, and time spent in closed arms. The subject was considered to be on the central platform or any arm when all 4 paws were within its perimeter. Pretreatment with saline or apremilast (20 mg/kg) was carried out 1 hour before saline or EtOH injections.
Locomotor Response to Novelty
The Opto-microvarimex animal activity meter (Columbus Instruments, Columbus, OH) was used to measure locomotor activity in standard cages covered by a plastic lid with holes for ventilation. On the day of the experiment, mice were placed in individual cages, and activity was monitored every 10 minutes for 22 hours. The first 80 minutes represent the drug effect on response to a novel situation (novelty). Saline or apremilast (20 mg/kg) was administered 1 hour before monitoring of motor activity. For chronic drug treatment, apremilast (20 mg/kg) was given daily for 6 days, and locomotor activity was measured on day 6, 1 hour after the last drug injection.
Loss of Righting Reflex
Sensitivity to the sedative effects of EtOH (3.6 g/kg, i.p.) was measured by the duration of LORR (Marley et al., 1986) . When mice became ataxic, they were placed in the supine position in V-shaped plastic troughs until they were able to right themselves 3 times within 30 seconds. Sleep time was defined as the time from being placed in the supine position until the righting reflex was regained. Saline or apremilast (20 mg/kg) was either injected once 1 hour before EtOH or daily for 6 days for chronic treatment.
Recovery from EtOH-Induced Motor Incoordination
EtOH impairs rotarod performance at doses above 1 g/kg (Johnston et al., 1986; Stromberg, 1988) . Mice were trained on a fixedspeed rotarod (Economex; Columbus Instruments) at 10 rpm until they were able to remain on the rotarod for 60 seconds. Every 15 minutes after EtOH injection (2 g/kg, i.p.), each mouse was placed on the rotarod, and latency to fall was measured until the mouse was able to remain on the rotarod for 60 seconds. Saline or apremilast (20 mg/kg) was either injected once 1 hour before EtOH or daily for 6 days for chronic treatment.
Acute Functional Tolerance
AFT to the ataxic effects of EtOH was determined using the 2-dose procedure (Erwin and Deitrich, 1996) . EtOH-na€ ıve mice were trained to balance on the rotarod (10 rpm) for a 60-second period. After training, half of the mice received saline and the other half received apremilast injections. One hour later, mice were given EtOH (1.75 g/kg, i.p.) and placed on the rotarod until they fell off. They were tested at 5-minute intervals until they could balance on the rotarod for 60 seconds. At this time (t1), a retro-orbital blood sample was collected to measure BEC1 as described below. Mice then received a second EtOH injection (2 g/kg, i.p.) and were tested in 5-minute intervals until they regained the ability to balance on the rotarod for 60 seconds (t2). Then a second blood sample was collected for BEC determination (BEC2). AFT was defined as the difference in BEC at t2 versus t1 (BEC2-BEC1).
Blood EtOH Concentration
Retro-orbital blood samples (~20 ll) were collected in capillary tubes and centrifuged for 6 minutes at 3,1009g using a Haematospin 1400 centrifuge (Analox Instruments, London, UK). Plasma samples were stored at À20°C until BECs were determined in 5-ll aliquots using an AM1 Alcohol Analyzer (Analox Instruments). The machine was calibrated every 15 samples using an industry standard, and BECs were determined using commercially available reagents according to the manufacturer's instructions. Samples were averaged from duplicate runs and BECs were expressed as mg/dl.
Statistical Analysis
Data are reported as mean AE SEM values. Prism (GraphPad Software, Inc., La Jolla, CA) was used to perform 1-or 2-way repeated measures analysis of variance (ANOVA), Bonferroni post hoc tests, and Student's t-tests.
RESULTS
Conditioned Taste Aversion
Intake was calculated as a percentage of trial 0 consumption for each mouse by dividing the amount of saccharin solution consumed in subsequent conditioning trials by the amount consumed in trial 0 (before conditioning). Compared with saline pretreatment (Fig. 1A, trial 2) , apremilast (20 mg/kg) pretreatment (Fig. 1B, trial 2) reduced saccharin (0.15% w/v) consumption (p < 0.001, Student's t-test). In saline-pretreated mice, EtOH (2.5 g/kg)-saccharin pairings significantly reduced saccharin consumption across trials (3-6), indicating development of CTA [F(1, 74) = 44.2, p < 0.0001, effect of pairing; F(3, 222) = 20.7, p < 0.0001, effect of trial; F(3, 222) = 9.1, p < 0.0001, pairing 9 trial interaction; Fig. 1A ]. In contrast, in apremilast-treated mice, EtOH-saccharin pairings did not reduce saccharin intake compared with the saline-paired group, suggesting lack of development of CTA [F(1, 73) = 0.11, p > 0.05, effect of pairing; F(3, 219) = 6.4, p < 0.001, effect of trial; Fig. 1B] . Comparison of control mice (saline-saline, Fig. 1A ) with apremilast-treated mice (saline-apremilast, Fig. 1B ) showed significant reduction in saccharin intake in the apremilastpretreated group [F(1, 71) = 30, p < 0.001, effect of pretreatment]. During extinction of EtOH-induced CTA, both saline-pretreated [F(1, 39) = 33.3, p < 0.0001, effect of pairing; F(7, 273) = 14.4, p < 0.0001, effect of time; F(7, 273) = 11.1, p < 0.0001, pairing 9 time interaction; Fig. 1C] and apremilast-pretreated [F(1, 39) = 5.4, p < 0.05, effect of pairing; F(7, 273) = 16, p < 0.0001, effect of time; F(7, 273) = 6.8, p < 0.0001, pairing 9 time interaction; Fig. 1D ] mice gradually increased preference for saccharin. Although apremilast-pretreated mice appeared to show faster extinction compared with the saline-paired group, this may be explained by their higher preference for saccharin from the beginning of the extinction period compared with saline-paired mice. We also note that the slopes of the extinction curves were similar for both groups, suggesting that apremilast did not affect extinction of CTA. Because apremilast-pretreated mice demonstrated extinction, we suggest that these mice also developed CTA to EtOH (albeit weaker than the saline-paired group), but this effect was masked by decreased saccharin consumption in the apremilast-saline group. There were no sex-dependent differences in these and the following CTA experiments, and data from male and female mice were combined.
We then tested the effects of LiCl (10 mEq/kg) on saccharin consumption. Similar to the results shown in Fig. 1 , compared with saline, pretreatment with apremilast (20 mg/kg) reduced saccharin consumption (p < 0.001, Student's t-test; Fig. 2A vs. B, trial 2) . In saline-treated mice, LiCl-saccharin pairings significantly reduced saccharin consumption across trials (3-6), indicating development of CTA [F(1, 46) = 43.4, p < 0.0001, effect of pairing; F(3, 138) = 31.4, p < 0.0001, effect of trial; F(3, 138) = 23.7, p < 0.0001, pairing 9 trial interaction; Fig. 2A ]. However in apremilast-treated mice, LiCl-saccharin pairings did not significantly reduce saccharin intake compared with saline-saccharin pairings, indicating lack of development of CTA [F(1, 44) = 3.19, p > 0.05, effect of pairing; F(3, 132) = 23.4, p < 0.0001, effect of trial; F(3, 132) = 13.27, p < 0.0001, pairing 9 trial interaction; Fig. 2B ]. Comparison of control mice (saline-saline; Fig. 2A ) with apremilast-treated mice (saline-apremilast; Fig. 2B ) showed significant reduction in saccharin intake in the apremilast-pretreated group [F(1, 54) = 15.6, p < 0.001, effect of pretreatment]. However, both saline-and apremilast-treated mice demonstrated strong initial aversion to saccharin during the extinction phase of LiCl-induced CTA, which was followed by a gradual increase in saccharin consumption over subsequent extinction sessions [F(1, 46) = 347, p < 0.0001, effect of pairing; F(7, 322) = 6.4, p < 0.0001, effect of time; F(7, 322) = 2.6, p < 0.05, pairing 9 time interaction for saline-pretreated groups; Fig. 2C ; and F(1, 43) = 292, p < 0.0001, effect of pairing; F(7, 301) = 12.3, p < 0.0001, effect of time; F(7, 301) = 7.4, p < 0.0001, pairing 9 time interaction for apremilast-pretreated groups; Fig. 2D ].
In the next experiment, we tested the ability of apremilast itself to serve as an unconditioned stimulus and induce CTA. Compared with saline, pairings with apremilast (20 mg/kg) reduced saccharin consumption across trials, indicating development of CTA [F(1, 22) = 17.3, p < 0.001, effect of treatment; Fig. 3A] . Apremilast-induced CTA led to a prolonged reduction in the preference for saccharin during extinction [F(1, 22) = 39.8, p < 0.0001, effect of treatment; F(7, 154) = 6.2, p < 0.0001, effect of time; F(7, 154) = 5.2, p < 0.0001, treatment 9 time interaction; Fig. 3B ].
Conditioned Place Preference
CPP is often used to examine the rewarding properties of EtOH and other drugs of abuse. Both saline-and apremilast (20 mg/kg)-pretreated groups showed CPP for EtOH as measured by the CPP score (p < 0.001; t-test for comparison of each group with a theoretical mean of 0; Fig. 4A ). Both groups of mice spent more time on the bar floor when it was paired with EtOH (Bar+) than when it was paired with saline (BarÀ) [F(1, 62) = 128, effect of pairing, p < 0.0001; Fig. 4B ]. There was no main effect of apremilast or interaction between apremilast and EtOH treatment on these measures. Locomotor activity during each 5-minute EtOH [CS+] and saline [CSÀ] conditioning trial is shown in Fig. 4C ,D. EtOH increased locomotor activity in mice pretreated with saline [F(1, 64) = 21.6, p < 0.0001, effect of EtOH; F(3, 192) = 4.2, p < 0.01, effect of trial; F(3, 192) = 28.3, p < 0.0001, EtOH 9 trial interaction; Fig. 4C ]. In mice pretreated with apremilast (20 mg/kg), there was a trial-dependent effect on locomotor activity [F(3, 192) = 7.6, p < 0.001, effect of trial; F(3, 192) = 14.1, p < 0.001, EtOH 9 trial interaction], but no effect of EtOH (Fig. 4D) . In both saline-and apremilast-pretreated mice, the [CSÀ] group showed a trial-dependent reduction in motor activity, as expected when animals habituate to the chamber [1-way ANOVA: F(3, 96) = 33.8, p < 0.0001, saline-treated mice; Fig. 4C ; F(3, 96) = 29.3, p < 0.0001, apremilast-pretreated mice; Fig. 4D ]. Trial-dependent increases in motor activity were observed in the [CS+] saline-pretreated group, indicating locomotor sensitization to EtOH [1-way ANOVA: F(3, 96) = 9.3, p < 0.0001], but this increase did not occur in the [CS+] apremilast-pretreated group [1-way ANOVA: F(3, 96) = 2.6, p > 0.05]. There were no sex-dependent differences, and data from male and female mice were combined.
Conditioned Place Avoidance
In the CPA procedure, there was an effect of EtOH in mice pretreated with apremilast as measured by the CPA score (p < 0.05, t-test for comparison with theoretical mean of 0) but not in mice pretreated with saline (Fig. 5A) . However, when we compared the time spent on the bar floor when it was paired with EtOH versus saline, there were significant effects of EtOH pairing, F(1, 66) = 13.7, p < 0.001, and apremilast pretreatment, F(1, 66) = 7.5, p < 0.01, but there was no interaction between them (Fig. 5B ). There were no sex-dependent differences, and data from male and female mice were combined.
Acute EtOH Withdrawal
A single EtOH dose (4 g/kg) suppressed basal HIC in all mice for~5-7 hours (Fig. 6A) . Recovery of HIC to the basal level was similar for saline-and apremilast (20 mg/kg)-pretreated mice (Fig. 6A) . No group differences were found for areas below or above the basal HIC level (Fig. 6B,C ). There were no sex-dependent differences, and data from male and female mice were combined. 
Elevated Plus Maze
In the elevated plus maze, locomotor activity was measured by the number of entries into the closed arms, and anxiety-like behavior was measured by the percentage of time spent in the open arms after saline or EtOH. There were no differences between the sexes, and data from male and female mice were combined. EtOH (Fig. 7C) . There was no effect of apremilast (20 mg/kg) on these responses.
Locomotor Response to Novelty
The initial 80 minutes of locomotor activity represents the drug effect on response to a novel situation (novelty). Analysis of this time period showed that acute administration of apremilast (20 mg/kg) significantly reduced the response to novelty in both male [F(7, 210) = 23.5, p < 0.0001, effect of time; F(1, 30) = 5.9, p < 0.05, effect of treatment; F(7, 210) = 3.1, p < 0.01, time 9 treatment interaction; Fig. 8A ] and female mice [F(7, 210) = 26, p < 0.0001, effect of time; F(1, 30) = 7.2, p < 0.05, effect of treatment; F(7, 210) = 4.5, p < 0.0001, time 9 treatment interaction; Fig. 8B ]. Because EtOH drinking was measured after chronic drug administration, we also studied motor activity after chronic (6 daily injections) administration of apremilast (20 mg/kg). Repeated treatment with apremilast significantly reduced the response to novelty in male mice [F(1, 30) = 7.9, p < 0.01, effect of treatment; F(7, 210) = 39.6, p < 0.0001, effect of time; F(7, 210) = 2.8, p < 0.01, time 9 treatment interaction; Fig. 8C ] but did not change the novelty response in female mice (Fig. 8D ).
Loss of Righting Reflex
As there is a positive correlation between the negative part of the HIC curve (protection from HIC) and duration of LORR (Blednov et al., 2012) , we next studied the effect of apremilast (20 mg/kg) on the duration of EtOH (3.6 g/kg)-induced LORR. Acute administration of apremilast increased the LORR duration (p < 0.001, Student's t-test; Fig. 9A ). Repeated administration of apremilast for 6 days also prolonged the LORR duration (p < 0.001, Student's ttest; Fig. 9B ). There were no sex-dependent differences, and data from male and female mice were combined.
Recovery from EtOH-Induced Motor Impairment
The rotarod test was used to measure the effects of apremilast (20 mg/kg) on EtOH (2 g/kg)-induced motor impairment. Both acute and chronic (6 daily injections) administration of apremilast prolonged the recovery from EtOH-induced motor impairment [ Fig. 10A , acute administration: F(1, 30) = 71.7, p < 0.0001, effect of treatment; F(10, 300) = 302.2, p < 0.0001, effect of time; F(10, 300) = 20.7, p < 0.0001, time 9 treatment interaction and Fig. 10B , chronic administration: F(1, 30) = 21.7, p < 0.0001, effect of treatment; F(7, 210) = 281.8, p < 0.0001, effect of time; F(7, 210) = 7.9, p < 0.0001, time 9 treatment interaction]. There were no sex-dependent differences, and data from male and female mice were combined.
Acute Functional Tolerance to EtOH-Induced Motor Impairment
We also used the rotarod test to measure acute tolerance to the ataxic effects of EtOH. The time to recover from motor impairment after the first and second EtOH injections was significantly longer in apremilast (20 mg/ kg)-pretreated versus saline-pretreated mice [F(1, 32) = 165, p < 0.0001, effect of pretreatment; F(1, 32) = 14,968, p < 0.0001, effect of recovery; F(1, 32) = 192, p < 0.0001, pretreatment 9 recovery interaction; Fig. 11A ]. The BECs measured after the first EtOH exposure (BEC1 after 1.75 g/kg EtOH) did not differ between groups, whereas BEC2 (after 2 g/kg EtOH) was lower in apremilast-versus saline-pretreated mice [F(1, 32) = 29.2, p < 0.001, effect of pretreatment; F(1, 32) = 5.6, p < 0.05, effect of recovery; F(1, 32) = 12.1, p < 0.01, pretreatment 9 recovery interaction; Fig. 11B ]. The difference in recovery time between the second and first EtOH injections was longer in apremilast-pretreated mice (p < 0.0001; Fig. 11C ). AFT (defined as BEC2-BEC1) to the intoxicating effects of EtOH was decreased in apremilast compared with saline-pretreated mice (63.5 AE 14.8 vs. À12.03 AE 15.9, p < 0.01; Fig. 11D ). There were no sex-dependent differences, and data from male and female mice were combined. Fig. 8 . Apremilast decreases the locomotor response to novelty. Acute administration of apremilast (20 mg/kg) reduced the novelty response in male (A; n = 16) and female (B; n = 16) mice. Repeated administration of apremilast (20 mg/kg) for 6 days reduced the novelty response in male (C; n = 16) and female (D; n = 16) mice (*p < 0.05 and **p < 0.01 compared with saline control by Bonferroni post hoc tests). 
DISCUSSION
The behavioral profile of apremilast has not previously been studied in detail. In this study, we tested the effects of apremilast on different behaviors that are correlated with EtOH consumption in mice and humans and that could potentially contribute to the reduced EtOH drinking reported in our companion paper (Blednov et al., 2018) . Table 1 summarizes the effects of apremilast (20 mg/kg) observed in both of our studies.
Apremilast did not alter development of EtOH-induced CPP, severity of acute EtOH withdrawal, or the anxiolyticlike effect of EtOH. Apremilast slightly increased the acquisition of CPA to EtOH. Locomotor responses to novelty were reduced in apremilast-treated mice. We note that rolipram, a prototype PDE4 inhibitor, reduced EtOH drinking in several rodent models Franklin et al., 2015; Wen et al., 2012) and also transiently reduced locomotor activity (Franklin et al., 2015; Wen et al., 2012) . Apremilast showed a similar pattern of effects-decreased EtOH consumption and a transient decrease in spontaneous motor activity.
Apremilast prolonged the duration of LORR and the recovery from acute motor incoordination induced by EtOH but did not alter EtOH clearance. Longer recovery from the intoxicating effects of EtOH may be due to the ability of apremilast to decrease AFT, although its initial central nervous system (CNS) depressant effects could also be a contributing factor. Increased sensitivity to ataxia, sedation, or Fig. 10 . Apremilast increases the duration of EtOH-induced motor impairment. Time on the rotarod after EtOH (2 g/kg, i.p.) following acute (A) and chronic (B; 6 daily injections) pretreatment with saline or 20 mg/kg of apremilast (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 compared with saline control by Bonferroni post hoc tests; n = 16 per group). Fig. 9 . Apremilast increases the duration of EtOH-induced loss of righting reflex (LORR). Duration of EtOH (3.6 g/kg)-induced LORR (in minutes) in saline-pretreated and apremilast (20 mg/kg)-pretreated male and female mice after acute (A; n = 11) and chronic (B; 6 daily injections, n = 6) exposure (***p < 0.001 compared with saline control by t-tests).
other adverse effects would be expected to decrease the amount of EtOH consumed. In humans, decreased sensitivity to alcohol was shown to be a predictor of future alcoholrelated problems (Schuckit, 1994) .
There is a positive correlation between preference for sweet solutions and EtOH consumption (Bachmanov et al., 1996; Blednov et al., 2008; Yoneyama et al., 2008) , but apremilast did not alter preference for saccharin or sucrose. EtOH-induced CPP is another behavior that is positively correlated with EtOH consumption (Green and Grahame, 2008) , but CPP was not affected by apremilast. However, locomotor activity recorded during conditioning trials of CPP suggested that apremilast limits the development of motor sensitization induced by EtOH, which may be correlated with EtOH consumption (Legastelois et al., 2014) . Apremilast slightly increased the acquisition of CPA to EtOH, suggesting an increase in EtOH's aversive properties.
The severity of acute withdrawal from EtOH is negatively correlated with EtOH drinking (Metten et al., 1998) , but pretreatment with apremilast did not change withdrawal severity in mice. CTA is also negatively correlated with voluntary EtOH consumption (Blednov et al., 2012; Green and Grahame, 2008; Risinger and Cunningham, 1998) . We found that apremilast had a complex effect on CTA. Although apremilast reduced the acquisition of CTA to EtOH and LiCl, this was confounded by its ability to reduce saccharin intake on its own. This may also be explained by the initial CNS depressant effects of apremilast, which could interfere with learning and general reward-mediated behaviors. For example, apremilast did not alter preference for sucrose or saccharin in 24-hour 2BC drinking tests (Blednov et al., 2018) , suggesting that the effects observed here are likely due to apremilast's acute CNS inhibitory actions. The apremilast-mediated reduction in saccharin intake was transient, because during extinction, control mice that received apremilast with paired injections of saline immediately showed high preference for saccharin. Overall, our results suggest that there was development of CTA to EtOH in apremilast-pretreated mice during the acquisition period; however, based on comparison of saline-and apremilast-pretreated mice during the extinction period, the CTA to EtOH was weaker in the apremilast group. In addition, when apremilast was used as the unconditioned stimulus, it induced CTA and may therefore evoke an aversive state independent of EtOH.
We also showed that apremilast significantly reduced the motor response to novelty. A positive relationship between the response to novelty and EtOH consumption in rodents has been observed in meta-analysis of behavioral phenotypes in several strains of mutant mice (Blednov et al., 2012) . In addition, a GeneNetwork analysis of the "BXD Published Phenotypes" shows correlations between 2BC EtOH consumption and measures of response to novelty in the open field (data in Record ID 10153 for EtOH preference in males are correlated with measures of activity in a novel open field test in Record IDs 11349, 11414, and 11863; http://www.ge nenetwork.org/webqtl/main.py). Although this was a different test of novelty than was used in our study, it indicates the generality of the association between EtOH consumption and the novelty response. Furthermore, the clinical literature suggests a relationship between novelty seeking and alcohol craving and relapse in alcohol-dependent patients (Evren et al., 2012) .
Voluntary EtOH consumption is correlated with different physiological and behavioral effects of EtOH (Green and Grahame, 2008) , and the cumulative effects could be significant if several behaviors are affected simultaneously (Blednov et al., 2012) . For example, apremilast increased EtOH's sedative and intoxicating effects, reduced AFT and response to novelty, potentially reduced some aspects of general reward, and increased the aversive properties of EtOH. Each of these actions would be expected to limit EtOH consumption on their own. Together, these changes may contribute to the robust decreases in EtOH drinking shown in our companion paper (Blednov et al., 2018) .
To distinguish between the peripheral versus central actions of apremilast following oral administration, we measured levels of apremilast in plasma, liver, and brain. Although plasma levels were expectedly higher, small amounts of apremilast did reach the brain 1 to 2 hours after a single oral dose (Blednov et al., 2018) . Furthermore, the plasma levels that we measured were similar to levels obtained with an equivalent dose in humans, suggesting that apremilast is a viable drug candidate for clinical testing in alcoholic subjects. These findings also provide novel evidence that apremilast can act centrally to decrease drinking-related behaviors in mice. At the mechanistic level, rolipram and other PDE4 inhibitors inhibit neuroimmune activation and dysregulation of GABA A a4 receptors produced by EtOH (Avila et al., 2017; Carlson et al., 2016) , and both neuroimmune and GABAergic signaling in brain have been implicated in the behavioral responses to EtOH (Blednov et al., 2017a, b; Lobo and Harris, 2008; Montesinos et al., 2016; Roberto and Varodayan, 2017; Robinson et al., 2014) . The cumulative actions of apremilast to decrease EtOH consumption and other related behaviors in a preclinical model suggest that this novel PDE4 inhibitor should be investigated further as a repurposed drug to treat AUD. Moreover, PDE4B was recently identified as a novel gene associated with alcohol consumption in humans (Clarke et al., 2017) . Subunit-selective PDE4 inhibitors, particularly those targeting PDE4A or PDE4B that are associated with anti-inflammatory activity (and not PDE4D which is associated with emetic effects), may reveal new drug treatments for AUD. AFT, acute functional tolerance; BEC, blood ethanol concentration; CPA, conditioned place avoidance; CPP, conditioned place preference; CTA, conditioned taste aversion; EPM, elevated plus maze; EtOH, ethanol; HIC, handling-induced convulsion; LiCl, lithium chloride; LORR, loss of righting reflex; 2BC, 2-bottle choice; 2BC-EOD, 2-bottle choice everyother-day; =, ↓, ↑ indicate no change, decreased, and increased responses in apremilast-pretreated compared with saline-pretreated (control) mice. Results for spontaneous motor activity and 2BC drinking experiments (EtOH, saccharin, sucrose) are from our companion paper (Blednov et al., 2018) .
